Toxoplasma gondii, IgG Antibodies. Screening.

Clinical information

Diagnostic Utility:

This is the qualitative detection of IgG antibodies against Toxoplasma gondii and its determination is useful in:

• Identifying exposure to the parasite that causes Toxoplasmosis.
• Progenitor cell transplantation, T lymphocyte transplantation, umbilical cord blood, solid organ transplantation, and in pregnant women.

Method:

Chemiluminescent microparticle immunoassay (CMIA).

Reference Values

Possible results are: Reactive and Non-Reactive.

Diagnostic Algorithm:

Not applicable.

Turnaround Time:

Maximum 2 working days.

Specimen information

Sample: Serum and/or plasma
Tube: 1-5 mL aliquots, plasma tubes with EDTA, sodium citrate, sodium heparin or lithium heparin as anticoagulants and/or serum tube with or without gel separator.
Minimum essential volume: 1 ml
Stability:

• At room temperature: ≤ 3 days
• In refrigeration: ≤ 14 days
• Sample frozen equal to or less than -30°C: 10 years

Transport instructions: Preferably refrigerated if it is whole blood tubes and refrigerated or frozen if it is serum and/or plasma aliquots.

Reason for rejection: Highly hemolyzed sample.

Administrative information

BST Code: 0154
Description of the test: Toxoplasma gondii, IgG Antibodies. Screening.
Synonyms: Toxo IgG
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates here.

Profiles:

Test 0154 Toxoplasma gondii, IgG Antibodies is usually requested together with the test for Toxoplasma gondii, IgM Antibodies.

References

• Inserts kits de Toxo IgG Architect, Abbott.

Quality

BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.